Get App
Moneycontrol

Co-Partners

Associate Partners

you are here: HomeNewsBusiness
Last Updated : May 17, 2019 10:35 PM IST | Source: PTI

USFDA inspection at Indore facility ends with zero observations: Cipla

'We would like to inform you that the USFDA (US Food and Drug Administration) conducted a post-approval inspection at our Indore facility from 13th May to 17th May, 2019. The inspection ended with zero observations,' the company said in a BSE filing.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Cipla May 17 said the US health regulator conducted a post-approval inspection at its Indore facility, and it ended with zero observations.

"We would like to inform you that the USFDA (US Food and Drug Administration) conducted a post-approval inspection at our Indore facility from 13th May to 17th May, 2019. The inspection ended with zero observations," the company said in a BSE filing.

Shares of Cipla closed at Rs 543.95 apiece on the BSE, down 1.2 per cent from its previous close.

Get Lok Sabha 2019 Live Election Results, constituency-wise tally, news, views and analysis
Follow our Lok Sabha Election Result Live Blog here.
First Published on May 17, 2019 10:29 pm
More From
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant